Global Markets for Enzyme Inhibitors -- Focus on Europe

News provided by

Sep 04, 2012, 07:14 ET

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Enzyme Inhibitors -- Focus on Europe

http://www.reportlinker.com/p0919321/Global-Markets-for-Enzyme-Inhibitors----Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY AND INFORMATION SOURCES

BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED REPORTS 3

BCC ON-LINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

CHAPTER 3 OVERVIEW 8

DEFINITIONS 8

STRUCTURE OF ENZYMES 8

ACTIVATION ENERGY 8

SPECIFICITY 8

ENZYME SUBSTRATE INTERACTION 9

CONDITIONS OF ENZYME ACTION 9

CLASSIFICATION OF ENZYMES 9

OXIDOREDUCTASES 10

TRANSFERASES 10

HYDROLASES 10

NUCLEASES 11

PHOSPHATASES 11

LYASES 11

ISOMERASES 11

LIGASES 11

REAL-LIFE APPLICATIONS OF ENZYMES 11

METABOLIC ENZYMES 12

DIGESTIVE ENZYMES 13

FOOD ENZYMES 14

NEED FOR ENZYMES IN HUMAN BODY 14

PROTEOLYTIC ENZYMES 14

LIPOLYTIC ENZYMES 15

AMYLOLYTIC ENZYMES 15

RENNIN ENZYMES 15

WHAT ARE ENZYME INHIBITORS 15

WHY ENZYME INHIBITION 15

USE OF ENZYME INHIBITORS 16

MECHANISM OF ENZYME INHIBITION 16

TYPES OF ENZYME INHIBITORS 16

MIXED INHIBITION 17

COMPETITIVE INHIBITION 17

CLASSIFICATION OF ENZYME INHIBITORS 17

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17

OXIDOREDUCTASE INHIBITORS 18

ALDOSE REDUCTASE INHIBITORS 18

STATINS 19

HISTORY OF DEVELOPMENT OF STATINS 19

TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19

5-ALPHA-REDUCTASE INHIBITORS 19

AROMATASE INHIBITORS 20

COX-2 INHIBITORS 20

HYDROLASE INHIBITORS 20

NEURAMINIDASE INHIBITORS 20

PROTEASE INHIBITORS 21

TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 22

PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS 22

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 22

TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23

PROTON PUMP INHIBITORS 23

TRANSFERASE INHIBITORS 23

PROTEIN KINASE INHIBITORS 23

REVERSE TRANSCRIPTASE INHIBITORS 24

CHAPTER 4 REGULATORY ASPECTS 26

TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26

TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29

TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30

CHAPTER 5 MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS 34

TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34

TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34

TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35

TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35

TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36

TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE

INHIBITORS 36

TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37

TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 37

TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38

CHAPTER 6 NEW DEVELOPMENTS 41

TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41

TABLE 18 CLINICAL TRIALS OF STATINS 42

TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 43

TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 44

TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 46

TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51

TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52

TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52

TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 53

TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54

NEW DRUGS IN CLINICAL TRIALS 55

TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55

CHAPTER 7 GLOBAL MARKETS 57

MARKET ANALYSIS 57

TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 58

FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 58

PROTON PUMP INHIBITORS 58

MARKET OVERVIEW 59

MARKET REVENUE 60

TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 60

FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 60

PROTEASE INHIBITORS 61

MARKET OVERVIEW 61

MARKET REVENUE 62

TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63

FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 63

REVERSE TRANSCRIPTASE INHIBITORS 63

MARKET OVERVIEW 64

MARKET REVENUE 65

TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 65

FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 65

KINASE INHIBITORS 66

MARKET OVERVIEW 66

MARKET REVENUE 68

TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 68

FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 68

STATINS 69

MARKET OVERVIEW 70

MARKET REVENUE 71

TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 71

FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 71

AROMATASE INHIBITORS 72

MARKET OVERVIEW 72

MARKET REVENUE 73

TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 73

FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 73

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 74

MARKET OVERVIEW 74

MARKET REVENUE 75

TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76

FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 76

NEURAMINIDASE INHIBITORS 76

MARKET OVERVIEW 77

MARKET REVENUE 77

TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 77

FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 77

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 78

MARKET OVERVIEW 79

MARKET REVENUE 79

TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 80

FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 80

MARKET SHARES 80

TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88

FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88

MARKET BY APPLICATIONS 89

TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE

SECTORS, THROUGH 2016 ($ MILLIONS) 90

FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/

DISEASE SECTORS, 2009-2016 ($ MILLIONS) 90

CARDIOVASCULAR (CV) DISEASE 90

TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

THROUGH 2016 ($ MILLIONS) 92

FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

2009-2016 ($ MILLIONS) 92

GASTROINTESTINAL DISORDERS 92

TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

THROUGH 2016 ($ MILLIONS) 93

FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

2009-2016 ($ MILLIONS) 93

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 94

TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 95

FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 95

HEPATITIS 96

TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 97

FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($

MILLIONS) 97

CANCER 98

TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH

2016 ($ MILLIONS) 100

FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($

MILLIONS) 100

ERECTILE DYSFUNCTION (ED) 100

TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 101

FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 101

OTHERS 102

TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016

($ MILLIONS) 103

FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($

MILLIONS) 103

GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION 103

TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 103

FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 104

CHAPTER 8 MARKETS IN EUROPE 106

MARKET ANALYSIS 106

TABLE 56 EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 107

FIGURE 29 EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 107

PROTON PUMP INHIBITORS 107

MARKET OVERVIEW 108

MARKET REVENUE 109

TABLE 57 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($

MILLIONS) 109

FIGURE 30 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 109

PROTEASE INHIBITORS 110

MARKET OVERVIEW 110

MARKET REVENUE 111

TABLE 58 EUROPEAN MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 111

FIGURE 31 EUROPEAN MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 111

REVERSE TRANSCRIPTASE INHIBITORS 112

MARKET OVERVIEW 112

MARKET REVENUE 113

TABLE 59 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 113

FIGURE 32 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 113

KINASE INHIBITORS 114

MARKET OVERVIEW 114

MARKET REVENUE 116

TABLE 60 EUROPEAN MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 116

FIGURE 33 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 116

STATINS 116

MARKET OVERVIEW 117

MARKET REVENUE 117

TABLE 61 EUROPEAN MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 118

FIGURE 34 EUROPEAN MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 118

AROMATASE INHIBITORS 118

MARKET OVERVIEW 119

MARKET REVENUE 119

TABLE 62 EUROPEAN MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 119

FIGURE 35 EUROPEAN MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 120

PDE5 INHIBITORS 120

MARKET OVERVIEW 120

MARKET REVENUE 121

TABLE 63 EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 121

FIGURE 36 EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 121

NEURAMINIDASE INHIBITORS 122

MARKET OVERVIEW 123

MARKET REVENUE 123

TABLE 64 EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 123

FIGURE 37 EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($

MILLIONS) 123

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 124

MARKET OVERVIEW 124

MARKET REVENUE 124

TABLE 65 EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 125

FIGURE 38 EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 125

MARKET SHARES OF INDUSTRY LEADERS IN EUROPE 125

PROTON PUMP INHIBITORS 125

TABLE 66 EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 125

FIGURE 39 EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 126

PROTEASE INHIBITORS 126

TABLE 67 EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010

(%) 127

FIGURE 40 EUROPEAN MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS,

2010 (%) 127

KINASE INHIBITORS 127

TABLE 68 EUROPEAN MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 127

FIGURE 41 EUROPEAN MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010

(%) 128

STATINS 128

TABLE 69 EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 129

FIGURE 42 EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 129

AROMATASE INHIBITORS 129

TABLE 70 EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,

2010 (%) 130

FIGURE 43 EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,

2010 (%) 130

REVERSE TRANSCRIPTASE INHIBITORS 130

TABLE 71 EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR

MANUFACTURERS, 2010 (%) 131

FIGURE 44 EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,

2010 (%) 131

PDE5 INHIBITORS 131

TABLE 72 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 132

FIGURE 45 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 132

NEURAMINIDASE INHIBITORS 132

TABLE 73 EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS,

2010 (%) 132

FIGURE 46 EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR

MANUFACTURERS, 2010 (%) 133

ACE INHIBITORS 133

TABLE 74 EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 133

FIGURE 47 EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 133

MARKET BY APPLICATIONS 134

TABLE 75 EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 135

FIGURE 48 EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, 2009-2016 ($ MILLIONS) 135

CARDIOVASCULAR (CV) DISEASES 135

TABLE 76 EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

THROUGH 2016 ($ MILLIONS) 137

FIGURE 49 EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

2009-2016 ($ MILLIONS) 137

GASTROINTESTINAL DISORDERS 138

TABLE 77 EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

THROUGH 2016 ($ MILLIONS) 138

FIGURE 50 EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

2009-2016 ($ MILLIONS) 138

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 139

TABLE 78 EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 140

FIGURE 51 EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($

MILLIONS) 140

CANCER 140

TABLE 79 EUROPEAN MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH

2016 ($ MILLIONS) 142

FIGURE 52 EUROPEAN MARKET OF ENZYME INHIBITORS IN CANCER, 2009-2016 ($

MILLIONS) 142

HEPATITIS 142

TABLE 80 EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 143

FIGURE 53 EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($

MILLIONS) 143

ERECTILE DYSFUNCTION 144

TABLE 81 EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 145

FIGURE 54 EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 145

OTHER DISEASES 145

TABLE 82 EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH

2016 ($ MILLIONS) 146

FIGURE 55 EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016

($ MILLIONS) 146

CHAPTER 9 PATENT ANALYSIS 148

PATENTS BY YEAR 148

TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 148

FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008-2012 148

FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008–2012 (%) 149

PATENTS BY TYPE 150

TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 150

FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 150

PATENTS BY COMPANY 151

TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 151

PATENTS BY COUNTRY 153

TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008-2012 153

FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008–2012 154

TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 154

FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%) 154

PATENTS BY ASSIGNEE 155

TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 155

FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 155

CHAPTER 10 CURRENT SITUATION 158

MARKET CONDITIONS 158

UNITED STATES 158

EUROPE 158

EMERGING MARKETS 158

TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 159

COMPETITION 159

PATENT EXPIRATIONS 159

UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT CLIFF 159

PATENT CHALLENGES / LEGAL PROCEEDINGS 159

NEW INDICATIONS APPROVED 160

NEW DRUG APPROVALS 160

RX- TO- OTC SWITCH 161

INCREASING NUMBER OF BABY BOOMERS 161

MERGERS AND ACQUISITIONS AND ALLIANCES 161

DIRECT-TO-CONSUMER ADVERTISING 162

CHAPTER 11 COMPANY PROFILES 164

ABBOTT LABORATORIES 164

AMGEN INC. 164

ASTRAZENECA PLC 165

AUROBINDO PHARMA 165

BAYER HEALTHCARE PHARMACEUTICALS 165

BOEHRINGER INGELHEIM GMBH 166

BRISTOL-MYERS SQUIBB 166

CIPLA LTD. 167

DR. REDDY'S LABORATORIES LTD. 167

EISAI INC. 168

ELI LILLY & CO. 168

ENDO PHARMACEUTICALS 169

GILEAD SCIENCES INC. 169

GLAXOSMITHKLINE PLC 170

GLENMARK GENERICS LTD. 170

HETERO DRUGS LTD. 171

HOFFMAN-LA ROCHE LTD. 171

INCYTE CORP. 171

JOHNSON & JOHNSON 172

LUPIN PHARMACEUTICALS INC. 172

MERCK & CO. INC. 173

MERCK SERONO SA 174

MYLAN LABORATORIES INC. 174

MYLAN LABORATORIES LTD. 175

NOVARTIS AG 175

NOVARTIS NORTH AMERICA 175

OSI PHARMACEUTICALS LLC 176

PAR PHARMACEUTICAL COMPANIES INC. 176

PFIZER INC. 176

RANBAXY LABORATORIES LTD. 177

ROXANE LABORATORIES LTD. 178

SANDOZ 178

SANOFI-AVENTIS 179

SANTARUS INC. 179

SUN PHARMACEUTICALS 180

TAKEDA PHARMACEUTICAL CO. LTD. 180

TEVA PHARMACEUTICAL INDUSTRIES LTD. 180

VERTEX PHARMACEUTICALS 181

VIIV HEALTHCARE 181

WATSON PHARMACEUTICALS INC. 182

CHAPTER 12 APPENDIX—ABBREVIATIONS 184

LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17

TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19

TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21

TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23

TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26

TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29

TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30

TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34

TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34

TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35

TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35

TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36

TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE

INHIBITORS 36

TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37

TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 37

TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38

TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41

TABLE 18 CLINICAL TRIALS OF STATINS 42

TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 43

TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 44

TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 46

TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51

TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52

TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52

TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 53

TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54

TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55

TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 58

TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 60

TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63

TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 65

TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 68

TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 71

TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 73

TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76

TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 77